Wells Fargo & Company Aptinyx Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.12 - $0.69 $0 - $3	5 Added 0.65%	772 $0
Q4 2022 Feb 13, 2023	SELL	$0.23 - $0.34 $113 - $167	-494 Reduced 39.18%	767 $0
Q3 2022 Nov 14, 2022	SELL	$0.35 - $0.72 $5 - $10	-15 Reduced 1.18%	1,261 $0
Q2 2022 Aug 12, 2022	BUY	$0.38 - $2.58 $274 - $1,862	722 Added 130.32%	1,276 $0
Q1 2022 May 16, 2022	BUY	$2.27 - $3.62 $456 - $727	201 Added 56.94%	554 $2,000
Q4 2021 Feb 14, 2022	BUY	$2.11 - $3.0 $211 - $300	100 Added 39.53%	353 $1,000
Q3 2021 Nov 15, 2021	SELL	$2.21 - $2.89 $33 - $43	-15 Reduced 5.6%	253 $1,000
Q2 2021 Aug 16, 2021	SELL	$2.39 - $3.5 $27,528 - $40,313	-11,518 Reduced 97.73%	268 $1,000
Q1 2021 May 13, 2021	SELL	$2.86 - $4.33 $112,083 - $169,692	-39,190 Reduced 76.88%	11,786 $35,000
Q4 2020 Feb 09, 2021	BUY	$2.93 - $4.3 $24,902 - $36,545	8,499 Added 20.01%	50,976 $177,000
Q3 2020 Nov 05, 2020	SELL	$3.05 - $4.99 $14,862 - $24,316	-4,873 Reduced 10.29%	42,477 $143,000
Q2 2020 Aug 13, 2020	BUY	$1.99 - $4.4 $93,888 - $207,592	47,180 Added 27752.94%	47,350 $198,000
Q1 2020 May 14, 2020	BUY	$1.81 - $5.03 $307 - $855	170 New	170 $0

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.